{
  "author": {
    "name": "Robert Langreth",
    "webUrl": "/author/profile/robert-langreth/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 3,
    "social": [],
    "articles": [
      {
        "uri": "/2019/03/13/rite-aid-shakeup/",
        "title": "Rite Aid Shakeup",
        "byline": "Robert Langreth",
        "kicker": "News",
        "prettyDate": "March 13, 2019",
        "timeToRead": "3 minute",
        "image": {
          "uri": "",
          "width": "",
          "height": ""
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth/",
            "name": "Robert Langreth"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Top managers, including CFO, will leave, and 400 jobs will be eliminated.",
        "body": null
      },
      {
        "uri": "/2017/12/04/cvs-aetna-deal-may-depend-on-trump-administrations/",
        "title": "CVS-Aetna Deal May Depend on Trump Administration’s Antitrust Approach",
        "byline": "Robert Langreth, David McLaughlin and Zachary Tracer, Bloomberg",
        "kicker": "News",
        "prettyDate": "December 04, 2017",
        "timeToRead": "5 minute",
        "image": {
          "uri": "",
          "width": "",
          "height": ""
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth-david-mclaughlin/",
            "name": "Robert Langreth, David McLaughlin"
          },
          {
            "webUrl": "/author/profile/zachary-tracer-bloomberg/",
            "name": "Zachary Tracer, Bloomberg"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Aetna shares are trading below CVS's $207 offer, signaling investor worry",
        "body": null
      },
      {
        "uri": "/2017/12/04/cvs-aetna-deal-may-depend-on-trump-administrations/",
        "title": "CVS-Aetna Deal May Depend on Trump Administration’s Antitrust Approach",
        "byline": " Robert Langreth, David McLaughlin and Zachary Tracer, Bloomberg ",
        "kicker": "News",
        "prettyDate": "December 04, 2017",
        "timeToRead": "5 minute",
        "image": {
          "uri": "",
          "width": "",
          "height": ""
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth-david-mclaughlin/",
            "name": "Robert Langreth, David McLaughlin"
          },
          {
            "webUrl": "/author/profile/zachary-tracer-bloomberg/",
            "name": "Zachary Tracer, Bloomberg"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Aetna shares are trading below CVS's $207 offer, signaling investor worry",
        "body": null
      }
    ]
  }
}